Structures of ferroportin in complex with its specific inhibitor vamifeport
eLife · 21.03.2023 · 12
DOI: 10.7554/elife.83053 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, online erschienen am 21.03.2023. Verfasst von Elena Farah Lehmann und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, University of Zurich, Zürich, Switzerland. Hauptthemen laut MEDLINE: Hepcidins, Cation Transport Proteins. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung.
Abstract (Originalsprache)
A central regulatory mechanism of iron homeostasis in humans involves ferroportin (FPN), the sole cellular iron exporter, and the peptide hormone hepcidin, which inhibits Fe 2+ transport and induces internalization and degradation of FPN. Dysregulation of the FPN/hepcidin axis leads to diverse pathological conditions, and consequently, pharmacological compounds that inhibit FPN-mediated iron transport are of high clinical interest. Here, we describe the cryo-electron microscopy structures of human FPN in complex with synthetic nanobodies and vamifeport (VIT-2763), the first clinical-stage oral FPN inhibitor. Vamifeport competes with hepcidin for FPN binding and is currently in clinical development for β-thalassemia and sickle cell disease. The structures display two distinct conformations of FPN, representing outward-facing and occluded states of the transporter. The vamifeport site is located in the center of the protein, where the overlap with hepcidin interactions underlies the competitive relationship between the two molecules. The introduction of point mutations in the binding pocket of vamifeport reduces its affinity to FPN, emphasizing the relevance of the structural data. Together, our study reveals conformational rearrangements of FPN that are of potential relevance for transport, and it provides initial insight into the pharmacological targeting of this unique iron efflux transporter.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, University of Zurich, Zürich, Switzerland.
- CSL Vifor, St. Gallen, Switzerland.
ORCID-Profile: Elena Farah Lehmann, Márton Liziczai, Katarzyna Drożdżyk, Franz Dürrenberger, Raimund Dutzler, Cristina Manatschal
Förderung
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
Zitieren
APA
Lehmann, E. F., Liziczai, M., Drożdżyk, K., Altermatt, P., Langini, C., Manolova, V., Sundstrom, H., Dürrenberger, F., Dutzler, R., & Manatschal, C. (2023). Structures of ferroportin in complex with its specific inhibitor vamifeport. eLife, 12. https://doi.org/10.7554/elife.83053
Vancouver
Lehmann EF, Liziczai M, Drożdżyk K, Altermatt P, Langini C, Manolova V, et al. Structures of ferroportin in complex with its specific inhibitor vamifeport. eLife. 2023;12. doi:10.7554/elife.83053
BibTeX
@article{Lehmann2023,
author = {Lehmann, Elena Farah and Liziczai, Márton and Drożdżyk, Katarzyna and Altermatt, Patrick and Langini, Cassiano and Manolova, Vania and Sundstrom, Hanna and Dürrenberger, Franz and Dutzler, Raimund and Manatschal, Cristina},
title = {Structures of ferroportin in complex with its specific inhibitor vamifeport},
journal = {eLife},
year = {2023},
volume = {12},
doi = {10.7554/elife.83053}
}
EUVIMED